ACLX
Arcellx, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Apr 28. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 34 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$1.101 → −$1.019 over 90 days. 3 up, 0 down in 30 days.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| JPMORGAN CHASE & CO | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | $0.00 |
| UBS Group AG | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Feb 2026| Date | Firm | Rating |
|---|---|---|
| Feb 26, 2026 | Guggenheim DOWNGRADE | Neutral |
| Feb 24, 2026 | Truist Securities DOWNGRADE | Hold |
| Feb 24, 2026 | Evercore ISI Group DOWNGRADE | In-Line |
| Feb 24, 2026 | UBS DOWNGRADE | Neutral |
| Feb 24, 2026 | Citigroup DOWNGRADE | Neutral |
| Feb 24, 2026 | Leerink Partners DOWNGRADE | Market Perform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Heery Christopher CHIEF MEDICAL OFFICER Apr 28, 2026 | TO ISSUER | 45,138 sh |
Ware Olivia C Director Apr 28, 2026 | TO ISSUER | 36,806 sh |
Gilson Michelle CHIEF FINANCIAL OFFICER Apr 28, 2026 | TO ISSUER | 20,496 sh |
Patel Kavita Director Apr 28, 2026 | TO ISSUER | 20,513 sh |
Heery Christopher CHIEF MEDICAL OFFICER Apr 28, 2026 | TO ISSUER | 40,000 sh |
Heery Christopher CHIEF MEDICAL OFFICER Apr 28, 2026 | TO ISSUER | 76,242 sh |
Patel Kavita Director Apr 28, 2026 | TO ISSUER | 11,459 sh |
Heery Christopher CHIEF MEDICAL OFFICER Apr 28, 2026 | TO ISSUER | 60,096 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.02 | -$1.11–-$0.95 | -0.1% | $6.8M |
| Next FY | -$1.48 | -$4.47–$1.95 | +14.5% | $274.3M |
| Next Q | -$1.06 | -$1.19–-$0.96 | +0.0% | $7.8M |
| Current FY | -$4.22 | -$4.77–-$3.85 | +0.0% | $68.8M |
SecBot reports
3 filings · 0 bullish · 2 bearish · 1 neutral- BEARISH 25-NSEApr 28, 2026
Arcellx, Inc. (ACLX) has been involuntarily delisted from Nasdaq, with the exchange filing a Form…
Traders should expect a catastrophic gap-down at the next available trading opportunity. The stock will likely trade on OTC markets with severely reduced liquidity. Monitor for any subsequent filing…
- NEUTRAL 10-K/AApr 24, 2026
Arcellx filed an amended 10-K/A to include Part III disclosures (director and executive…
This is a routine procedural filing with no material impact. Traders should note that all Part III information is now available and no further proxy statement incorporation is needed. Monitor the…
- BEARISH CLUSTERFeb 25, 2026
Two corporate insiders at Arcellx, Inc. (ACLX) sold shares in the past week, including CFO…
CFO and another insider selling material amounts of stock simultaneously raises concerns about confidence in near-term prospects; traders should monitor for downward price pressure and any upcoming…
All ACLX filing & press-release reports (3)
- 25-NSE reportApr 28, 2026
- 10-K/A reportApr 24, 2026
- CLUSTER reportFeb 25, 2026